Multiparametric flow cytometry profiling of neoplastic plasma cells in multiple myeloma

Cytometry Part B - Clinical Cytometry

Volumn 78, Issue 5, 2010, Pages 338-347

  Johnsen, Hans E ^a,b   Bøgsted, Martin ^a   Klausen, Tobias W ^b   Gimsing, Peter ^c   Schmitz, Alexander ^a   Kjærsgaard, Erik ^b   Damgaard, Tina ^b   Voss, Pia ^b   Knudsen, Lene M ^b,d   Mylin, Anne K ^b,c   Nielsen, Johan Lanng ^e   Björkstrand, Bo ^f   Gruber, Astrid ^f   Lenhoff, Stig ^g   Remes, Kari ^h   Dahl, Inger Marie ⁱ   Fogd, Kirsten ^a   Dybkær, Karen ^a  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c Rigshospitalet   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

^h TURKU UNIVERSITY HOSPITAL   (Finland)

ⁱ UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Diagnosis; Flow cytometry profiling; Multiple myeloma

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD27 ANTIGEN; CD28 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CELL SURFACE MARKER; HERMES ANTIGEN; CD38 PROTEIN, HUMAN; MELPHALAN; MEMBRANE PROTEIN; PTPRC PROTEIN, HUMAN;

ANTIGEN EXPRESSION; ARTICLE; CELL DIFFERENTIATION; CYTOLOGY; FLOW CYTOMETRY; FOLLOW UP; HUMAN; IMMUNOFLUORESCENCE; LIGHT SCATTERING; MAJOR CLINICAL STUDY; MICROSCOPY; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; PLASMA CELL; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; ADULT; AGED; BLOOD; CLINICAL TRIAL (TOPIC); EVALUATION; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; PLASMACYTOMA; RETROSPECTIVE STUDY; STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CANCER CELL; CANCER DIAGNOSIS; CANCER RISK; CANCER SURVIVAL; CELL COUNT; CLINICAL PRACTICE; CLUSTER ANALYSIS; CONTROLLED STUDY; DRUG MEGADOSE; FLUORESCENCE; HUMAN CELL; HUMAN TISSUE; MULTIPARAMETRIC FLOW CYTOMETRY; SINGLE DRUG DOSE; STAINING;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD38; ANTIGENS, CD45; CLINICAL TRIALS AS TOPIC; FLOW CYTOMETRY; HUMANS; MELPHALAN; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASMS, PLASMA CELL; PROGNOSIS; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; YOUNG ADULT;

EID: 77956572458     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.20523     Document Type: Article

References (79)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008.
2. Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. Blood 2008;111:3941-3967.
3. Perez-Persona E, Vidriales MB, Mateo G, Garcia-Sanz R, Mateos MV, de Coca AG, Galende J, Martín-Nuñez G, Alonso JM, de Las Heras N, Hernández JM, Martín A, López-Berges C, Orfao A, San Miguel JF. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smouldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007;110:2586-2592.
4. Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 2004;121:482-428.
5. San Miguel JF, Almeida J, Mateo G, Blade J, Lopez-Berges C, Caballero D, Hernández J, Moro MJ, Fernández-Calvo J, Díaz-Mediavilla J, Palomera L, Orfao A. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: A tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood 2002;99:1853-1856.
6. Mateo G, Montalbán MA, Vidriales MB, Lahuerta JJ, Mateos MV, Gutiérrez N, Rosiñol L, Montejano L, Bladé J, Martínez R, de la Rubia J, Diaz-Mediavilla J, Sureda A, Ribera JM, Ojanguren JM, de Arriba F, Palomera L, Terol MJ, Orfao A, San Miguel JF; PETHEMA Study Group; GEM Study Group. Prognostic value of immunophenotyping in multiple myeloma: A study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with highdose therapy. J Clin Oncol 2008;26:2737-2744.
7. Rasmussen T, Jensen L, Johnsen HE. The Clonal Hierachy in Multiple Myeloma. Acta Oncol 2001;39:765-770.
8. Sezer O, Heider U, Zavrski I, Possinger K. Differentiation of MGUS and multiple myeloma using flow cytometric characteristics of plasma cells. Haematologica 2001;86:837-843.
9. Ocqueteau M, Orfao A, Almeida J, Blade J, Gonzalez M, Garcia-Sanz R, López-Berges C, Moro MJ, Hernández J, Escribano L, Caballero D, Rozman M, San Miguel JF. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol 1998;152:1655-1665.
10. Manzanera GM, San Miguel Izquierdo JF, Orfao de Matos A. Immunophenotyping of plasma cells in multiple myeloma. Methods Mol Med 2005;113:5-24.
11. Mateo G, Castellanos M, Rasillo A, Gutierrez NC, Montalban MA, Martin ML, Hernández JM, López-Berges MC, Montejano L, Bladé J, Mateos MV, Sureda A, de la Rubia J, Díaz-Mediavilla J, Pandiella A, Lahuerta JJ, Orfao A, San Miguel JF. Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res 2005;11:3661-3667.
12. Perez-Andres M, Almeida J, Martin-Ayuso M, De Las Heras N, Moro MJ, Martin-Nuñez G, Galende J, Cuello R, Abuín I, Moreno I, Domínguez M, Hernandez J, Mateo G, San Miguel JF, Orfao A. Soluble and membrane levels of molecules involved in the interaction between clonal plasma cells and the immunological microenvironment in multiple myeloma and their association with the characteristics of the disease. Int J Cancer 2009;124:367-375.
13. Robillard N, Pellat-Deceunynck C, Bataille R. Phenotypic characterization of the human myeloma cell growth fraction. Blood 2005;105:4845-4848.
14. Rawstron AC, Davies FE, DasGupta R, Ashcroft AJ, Patmore R, Drayson MT, Owen RG, Jack AS, Child JA, Morgan G. Flow cytometric disease monitoring in multiple myeloma: The relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 2002;100:3095-3100.
15. de Tute RM, Jack AS, Child JA, Morgan GJ, Owen RG, Rawstron AC. A single-tube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma. Leukemia 2007;21:2046-2049.
16. Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H, Dalva K, Fuhler G, Gratama J, Hose D, Kovarova L, Lioznov M, Mateo G, Morilla R, Mylin AK, Omedé P, Pellat-Deceunynck C, Perez Andres M, Petrucci M, Ruggeri M, Rymkiewicz G, Schmitz A, Schreder M, Seynaeve C, Spacek M, de Tute RM, Van Valckenborgh E, Weston-Bell N, Owen RG, San Miguel JF, Sonneveld P, Johnsen HE; European Myeloma Network. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008;93:431-438.
17. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-1473.
18. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-1123.
19. Kyle AR, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351: 1860-1873.
20. Higgins MJ, Fonseca R. Genetics of multiple myeloma. Best Pract Res Clin Haematol 2005;18:525-536.
21. Hallek M, Leif BP, Anderson KC. Multiple myeloma: Increasing evidence for a multistep transformation process. Blood 1998;91:3-21.
22. Rasmussen T, Theilgaard-Monch K, Hudlebusch HR, Lodahl M, Johnsen HE, Dahl IM. Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: Indications for different disease entities. Br J Haematol 2003;123:253-262.
23. Rasmussen T, Kuehl M, Lodahl M, Johnsen HE, Dahl IMS. Possible roles for activating RAS mutations in MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood 2005;105:317-323.
24. Davies FE, Dring AM, Li C, Rawstron AC, Shammas MA, O'Connor SM, Fenton JA, Hideshima T, Chauhan D, Tai IT, Robinson E, Auclair D, Rees K, Gonzalez D, Ashcroft AJ, Dasgupta R, Mitsiades C, Mitsiades N, Chen LB, Wong WH, Munshi NC, Morgan GJ, Anderson KC. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood 2003;102:4504-4511.
25. Maynadié M, Picard F, Husson B, Chatelain B, Cornet Y, Le Roux G, Campos L, Dromelet A, Lepelley P, Jouault H, Imbert M, Rosenwadj M, Vergé V, Bissières P, Raphaël M, Béné MC, Feuillard J; Groupe d'Etude Immunologique des Leucémies (GEIL). Immunophenotypic clustering of myelodysplastic syndromes. Blood 2002;100:2349-2356.
26. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL, Wislöff F, Brinch L, Carlson K, Carlsson M, Dahl IM, Gimsing P, Hippe E, Johnsen H, Lamvik J, Löfvenberg E, Nesthus I, Rödjer S. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: A population-based study. Nordic Myeloma Study Group. Blood 2000;95:7-11.
27. Mellqvist UH, Lenhoff S, Johnsen HE, Hjorth M, Holmberg E, Juliusson G, Tangen JM, Westin J; Nordic Myeloma Study Group. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Results of a randomized comparison with vincristine, doxorubicin, and dexamethasone. Cancer 2008;112:129-135.
28. Lenhoff S, Hjorth M, Turesson I, Westin J, Gimsing P, Wislöff F, Ahlberg L, Carlson K, Christiansen I, Dahl IM, Forsberg K, Brinch L, Hammerström J, Johnsen HE, Knudsen LM, Linder O, Mellqvist UH, Nesthus I, Nielsen JL; Nordic Myeloma Study Group. Intensive therapy for multiple myeloma in patients younger than 60 years. Longterm results focusing on the effect of the degree of response on survival and relapse pattern after transplantation. Haematologica 2006;91:1228-1233.
29. Lenhoff S, Hjorth M, Westin J, Brinch L, Bäckström B, Carlson K, Christiansen I, Dahl IM, Gimsing P, Hammerström J, Johnsen HE, Juliusson G, Linder O, Mellqvist UH, Nesthus I, Nielsen JL, Tangen JM, Turesson I; Nordic Myeloma Study Group. Impact of age on survival after intensive therapy for multiple myeloma: A populationbased study by the Nordic Myeloma Study Group. Br J Haematol 2006;133:389-396.
30. Björkstrand B, Rasmussen T, Remes K, Gruber A, Pelliniemi TT, Johnsen HE. Feasibility of fludarabine added to VAD during induction therapy in multiple myeloma: A randomised phase II-study. Eur J Haematol 2003;70:379-383.
31. Johnsen HE, Knudsen LM, Mylin AK, Gimsing P, Gregersen H, Abildgaard N, Andersen NF, Plesner T, Vangsted A, Mourits-Andersen T. Up-front fludarabine impairs stem cell harvest in multiple myeloma: report from an interim analysis of the NMSG 13/03 randomized placebo controlled phase II trial. Hematology Reviews 2009;1:e11 (http://www.pagepress.org/journals/index.php/hr/article/view/ hr.2009.e11).
32. Johnsen HE, Björkstrand B, Klausen TW, Remes K, Gruber A, Knudsen LM, Bergmann OJ, Lenhoff S. Double vs. single high dose melphalan 200 mg/m2 and autologous stem cell transplantation for multiple myeloma: a region-based study in 484 patients from the Nordic. Hematology Reviews 2009;1:e2 (http://www.pagepress. org/journals/index.php/hr/article/view/hr.2009.e2).
33. Johnsen HE, Lanza F. Quality assessment of autologous haematopoietic blood progenitor and stem cell grafting: A prospective registration study. J Biol Regul Homeost Agents 2002;16:272-288.
34. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol 2003;121:749-757.
35. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton LJ 3rd. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346:564-569.
36. Gregersen H, Mellemkjaer L, Ibsen JS, Dahlerup JF, Thomassen L, Sørensen H. The impact of M-component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance. Haematologica 2001;86:1172-1179.
37. Svane IM, Nikolajsen K, Johnsen HE. Antigen-specific T-cell immunity in multiple myeloma patients is restored following high-dose therapy: Implications for timing of vaccination. Scand J Immunol 2007;66:465-475.
38. Mylin AK, Rasmussen T, Johansen JS, Knudsen LM, Noergaard PH, Lenhoff S, Dahl IM, Johnsen HE; the Nordic Myeloma Study Group. Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells. Eur J Haematol 2006;77:416-424.
39. Roer O, Hammerström J, Lenhoff S, Mylin AK, Knudsen LM, Rasmussen T, Johnsen HE; Nordic Myeloma Study Group. Quality assessment of autografting by probability evaluation: Model estimation by clinical end-points in newly diagnosed multiple myeloma patients. Cytotherapy 2006;8:79-88.
40. Brimnes MK, Svane IM, Johnsen HE. Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma. Clin Exp Immunol 2006;144:76-84.
41. Hudlebusch HR, Theilgaard-Munch K, Lodahl M, Johnsen HE, Rasmussen T. Identification of ID-1 as a potential target gene of MMSET in multiple myeloma. Br J Haematol 2005;130:700-708.
42. Hudlebusch HR, Lodahl M, Johnsen HE, Rasmussen T. Expression of HOXA genes in patients with multiple myeloma. Leuk Lymphoma 2004;45:1215-1217.
43. Rasmussen T, Lodahl M, Hancke S, Johnsen HE. In multiple myeloma clonotypic CD38-/CD19+/CD27+ memory B cells recirculate through bone marrow, peripheral blood and lymph nodes. Leuk Lymphoma 2004;45:1413-1417.
44. Do TH, Johnsen HE, Kjaersgaard E, Taaning E, Svane IM. Impaired circulating myeloid DCs from myeloma patients. Cytotherapy 2004;6:196-203.
45. Rasmussen T, Knudsen LM, Huynh TK, Johnsen HE. Molecular and clinical follow-up after treatment of multiple myeloma. Acta Haematol 2004;112:105-110.
46. Rasmussen T, Knudsen LM, Dahl IM, Johnsen HE. C-MAF oncogene dysregulation in multiple myeloma: Frequency and biological relevance. Leuk Lymphoma 2003;44:1761-1766.
47. Rasmussen T, Hansson L, Osterborg A, Johnsen HE, Mellstedt H. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood 2003;101:4607-4610.
48. Rasmussen T, Hudlebusch HR, Knudsen LM, Johnsen HE. FGFR3 dysregulation and clinical outcome in myeloma. Br J Haematol 2003;120:166. No abstract available.
49. Rasmussen T, Jensen L, Johnsen HE. The CD19 compartment in myeloma includes a population of clonal cells persistent after highdose treatment. Leuk Lymphoma 2002;43:1075-1077.
50. Rasmussen T, Hudlebusch HR, Knudsen LM, Johnsen HE. FGFR3 dysregulation in multiple myeloma: Frequency and prognostic relevance. Br J Haematol 2002;117:626-628.
51. Rasmussen T, Knudsen LM, Johnsen HE. Frequency and prognostic relevance of cyclin D1 dysregulation in multiple myeloma. Eur J Haematol 2001;67:296-301.
52. Knudsen LM, Rasmussen T, Nikolaisen K, Johnsen HE. Mobilisation of tumour cells along with CD34+ cells to peripheral blood in multiple myeloma. Eur J Haematol 2001;67:289-295.
53. Rasmussen T, Björkstrand B, Andersen H, Gaarsdal E, Johnsen HE. Efficacy and safety of CD34-selected and CD19-depleted autografting in multiple myeloma patients: A pilot study. Exp Hematol 2002;30:82-88.
54. Rasmussen T, Jensen L, Johnsen HE. The clonal hierachy in multiple myeloma. Acta Oncol 2000;39:765-770.
55. Rasmussen T, Jensen L, Honore L, Johnsen HE. Frequency and kinetics of polyclonal and clonal B cells in the peripheral blood of patients being treated for multiple myeloma. Blood 2000;96:4357-4359.
56. TerpstraWE, LokhorstHM, Blomjous F,Meuwissen OJ, Dekker AW. Comparison of plasma cell infiltration in bone marrow biopsies and aspirates in patientswith multiplemyeloma. Br J Haematol 1992;82:46-49.
57. Wei A, Juneja S. Bone marrow immunohistology of plasma cell neoplasms. J Clin Pathol 2003;56:406-411. (Pubitemid 36724205)
58. Wei A, Westerman D, Feleppa F, Trivett M, Juneja S. Bone marrow plasma cell microaggregates detected by immunohistology predict earlier relapse in patients with minimal disease after high-dose therapy for myeloma. Haematologica 2005;90:1147-1149.
59. Nadav L, Katz BZ, Baron S, Yossipov L, Polliack A, Deutsch V, Geiger B, Naparstek E. Diverse niches within multiple myeloma bone marrow aspirates affect plasma cell enumeration. Br J Haematol 2006;133:530-532.
60. Kaufman L, Rousseeuw PJ. Finding Groups in Data: An Introduction to Cluster Analysis. New York: Wiley; 1990.
61. Thiery JP, Brackenbury R, Rutishauser U, Edelman GM. Adhesion among neural cells of the chick embryo. II. Purification and characterization of a cell adhesion molecule from neural retina. J Biol Chem 1977;252:6841-6845.
62. Moran N, Bock E. Characterization of the kinetics of neural cell adhesion molecule homophilic binding. FEBS Lett 1988;242:121-124.
63. Probstmeier R, Kuhn K, Schachner M. Binding properties of the neural cell adhesion molecule to different components of the extracellular matrix. J. Neurochem 1989;53:1794-1801.
64. Kadmon G, Kowitz A, Altevogt P, Schachner M. The neural cell adhesion molecule N-CAM enhances L1-dependent cell-cell interactions. J Cell Biol 1990;110:193-208.
65. Pellat-Deceunynck C, Puthier D, Rapp MJ, Harousseau J, Bataille R, Amiot M. Adhesion molecules on human myeloma cells: Significant changes in expression related to malignancy, tumor spreading, and immortalization. Cancer Res 1995;55:3647-3653.
66. Dahl IM, Rasmussen T, Kauric G, Husebekk A. Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma. Br J Haematol 2002;116:273-277.
67. Ely SA, Knowles DM. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. Am J Pathol 2002;160:1293-1299.
68. Pellat-Deceunynck C, Bataille R, Robillard N, Harousseau JL, Rapp MJ, Juge-Morineau N, Wijdenes J, Amiot M. Expression of CD28 and CD40 in human myeloma cells: A comparative study with normal plasma cells. Blood 1994;84:2597-2603.
69. Sahara N, Takeshita A, Shigeno K, Fujisawa S, Takeshita K, Naito K, Ihara M, Ono T, Tamashima S, Nara K, Ohnishi K, Ohno R. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Haematol 2002;117:882-885.
70. Robillard N, Avet-Loiseau H, Garand R, Moreau P, Pineau D, Rapp MJ, Harousseau JL, Bataille R. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood 2003;102:1070-1071.
71. Moreau P, Robillard N, Jego G, Pellat C, Le GS, Thoumi S, et al. Lack of CD27 in myeloma delineates different presentation and outcome. Br J Haematol 2006;132:168-170.
72. Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, Legouffe E, et al. CD200 is a new prognostic factor in multiple myeloma. Blood 2006;108:4194-4197.
73. Sahara N, Takeshita A, Shigeno K, Fujisawa S, Takeshita K, Naito K, Ihara M, Ono T, Tamashima S, Nara K, Ohnishi K, Ohno R. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Haematol 2002;117:882-885.
74. Sahara N, Takeshita A. Prognostic significance of surface markers expressed in multiple myeloma: CD56 and other antigens. Leuk Lymphoma 2004;45:61-65.
75. Moreau P, Robillard N, Avet-Loiseau H, Pineau D, Morineau N, Milpied N, Harousseau JL, Bataille R. Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma. Haematologica 2004;89:547-551.
76. Kumar S, Rajkumar SV, Kimlinger T, Greipp PR, Witzig TE. CD45 expression by bone marrow plasma cells in multiple myeloma: Clinical and biological correlations. Leukemia 2005;19:1466-1470.
77. Paiva B, Vidriales MB, Cerveró J, Mateo G, Pérez JJ, Montalbán MA, Sureda A, Montejano L, Gutiérrez NC, García de Coca A, de Las Heras N, Mateos MV, López-Berges MC, García-Boyero R, Galende J, Hernández J, Palomera L, Carrera D, Martínez R, de la Rubia J, Martín A, Bladé J, Lahuerta JJ, Orfao A, San Miguel JF; GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Groups. Blood 2008;112:4017-4023.
78. Damgaard T, Knudsen LM, Dahl IM, Gimsing P, Lodahl M, Rasmussen T. Regulation of the CD56 promoter and its association with proliferation, anti-apoptosis and clinical factors in multiple myeloma. Leuk Lymphoma 2009;50:236-246.
79. Paiva B, Vidriales M-B, Pérez JJ, Mateo G, Montalbán MA, Mateos MV, Bladé J, Lahuerta JJ, Orfao A, San Miguel JF. Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. Haematologica 2009;94:1599-1602.